However, in our two-tumor mouse model, CD8+ T cells expressing both an anti-Her2 CAR and anti-CD19 iCAR failed to effectively block CAR T cell killing of the dual-antigen (Her2+, CD19+) tumor (Fig. 3D). Here, ERBB2 is linked to neoplasm.